Criteria	B:C0679228
sets	O
for	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
are	O
not	O
adequate	O
for	O
those	O
presenting	O
with	O
extraglandular	O
organ	O
involvements	O
as	O
their	O
dominant	O
clinical	I:C0243095
features	I:C0243095
.	O

Criteria	O
sets	O
for	O
primary	B:C0151449
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
are	O
not	O
adequate	O
for	O
those	O
presenting	O
with	O
extraglandular	O
organ	O
involvements	O
as	O
their	O
dominant	O
clinical	I:C0243095
features	I:C0243095
.	O

Criteria	O
sets	O
for	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
are	O
not	O
adequate	O
for	O
those	O
presenting	O
with	O
extraglandular	O
organ	B:C0178784
involvements	O
as	O
their	O
dominant	O
clinical	I:C0243095
features	I:C0243095
.	O

Criteria	O
sets	O
for	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
are	O
not	O
adequate	O
for	O
those	O
presenting	O
with	O
extraglandular	O
organ	O
involvements	O
as	O
their	O
dominant	B:C0243095
clinical	I:C0243095
features	I:C0243095
.	O

Patients	O
with	O
primary	B:C0151449
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
(	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
)	O
may	O
go	O
undiagnosed	O
or	O
be	O
misclassified	O
due	O
to	O
the	O
insidious	O
nature	O
and	O
wide	O
spectrum	O
of	O
the	O
disease	O
.	O

Patients	O
with	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
(	O
primary	B:C0151449
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
)	O
may	O
go	O
undiagnosed	O
or	O
be	O
misclassified	O
due	O
to	O
the	O
insidious	O
nature	O
and	O
wide	O
spectrum	O
of	O
the	O
disease	O
.	O

Patients	O
with	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
(	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
)	O
may	O
go	O
undiagnosed	B:C1408353
or	O
be	O
misclassified	O
due	O
to	O
the	O
insidious	O
nature	O
and	O
wide	O
spectrum	O
of	O
the	O
disease	O
.	O

Patients	O
with	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
(	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
)	O
may	O
go	O
undiagnosed	O
or	O
be	O
misclassified	O
due	O
to	O
the	O
insidious	O
nature	O
and	O
wide	O
spectrum	O
of	O
the	O
disease	B:C0012634
.	O

The	O
available	O
several	O
classification	B:C0008902
criteria	O
emphasize	O
glandular	O
findings	O
.	O

The	O
available	O
several	O
classification	O
criteria	B:C0679228
emphasize	O
glandular	O
findings	O
.	O

The	O
available	O
several	O
classification	O
criteria	O
emphasize	O
glandular	B:C1285092
findings	O
.	O

The	O
available	O
several	O
classification	O
criteria	O
emphasize	O
glandular	O
findings	B:C0243095
.	O

We	O
aimed	O
to	O
analyze	B:C0936012
the	O
efficiency	O
of	O
various	O
classification	O
criteria	O
sets	O
in	O
patients	O
diagnosed	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	O
with	O
those	O
who	O
did	O
not	O
.	O

We	O
aimed	O
to	O
analyze	O
the	O
efficiency	O
of	O
various	O
classification	B:C0008902
criteria	O
sets	O
in	O
patients	O
diagnosed	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	O
with	O
those	O
who	O
did	O
not	O
.	O

We	O
aimed	O
to	O
analyze	O
the	O
efficiency	O
of	O
various	O
classification	O
criteria	B:C0679228
sets	O
in	O
patients	O
diagnosed	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	O
with	O
those	O
who	O
did	O
not	O
.	O

We	O
aimed	O
to	O
analyze	O
the	O
efficiency	O
of	O
various	O
classification	O
criteria	O
sets	O
in	O
patients	O
diagnosed	B:C0011900
on	O
the	O
clinical	O
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	O
with	O
those	O
who	O
did	O
not	O
.	O

We	O
aimed	O
to	O
analyze	O
the	O
efficiency	O
of	O
various	O
classification	O
criteria	O
sets	O
in	O
patients	O
diagnosed	O
on	O
the	O
clinical	B:C0008976
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	O
with	O
those	O
who	O
did	O
not	O
.	O

We	O
aimed	O
to	O
analyze	O
the	O
efficiency	O
of	O
various	O
classification	O
criteria	O
sets	O
in	O
patients	O
diagnosed	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	B:C0151449
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	O
with	O
those	O
who	O
did	O
not	O
.	O

We	O
aimed	O
to	O
analyze	O
the	O
efficiency	O
of	O
various	O
classification	O
criteria	O
sets	O
in	O
patients	O
diagnosed	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
expert	O
opinion	O
and	O
to	O
compare	O
those	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
patients	O
who	O
fulfilled	O
these	O
criteria	B:C0679228
with	O
those	O
who	O
did	O
not	O
.	O

This	O
is	O
a	O
multicenter	B:C1096776
study	I:C1096776
in	O
which	O
834	O
patients	O
from	O
22	O
university	O
-	I:C3812871
based	I:C3812871
rheumatology	I:C3812871
clinics	I:C3812871
are	O
included	O
.	O

This	O
is	O
a	O
multicenter	O
study	I:C1096776
in	O
which	O
834	O
patients	O
from	O
22	O
university	B:C3812871
-	I:C3812871
based	I:C3812871
rheumatology	I:C3812871
clinics	I:C3812871
are	O
included	O
.	O

Diagnosis	B:C0011900
of	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
was	O
made	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
the	O
expert	O
opinion	O
.	O

Diagnosis	O
of	O
primary	B:C0151449
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
was	O
made	O
on	O
the	O
clinical	O
basis	I:C0008976
by	O
the	O
expert	O
opinion	O
.	O

Diagnosis	O
of	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
was	O
made	O
on	O
the	O
clinical	B:C0008976
basis	I:C0008976
by	O
the	O
expert	O
opinion	O
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
only	O
interviewed	O
patients	O
once	O
and	O
collected	O
available	O
data	O
from	O
the	O
medical	O
records	I:C0025102
.	O

In	O
this	O
study	O
,	O
we	O
only	O
interviewed	O
patients	O
once	O
and	O
collected	O
available	O
data	O
from	O
the	O
medical	B:C0025102
records	I:C0025102
.	O

The	O
European	B:C0679228
criteria	I:C0679228
,	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
(	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
)	O
and	O
American	O
College	I:C0679228
of	I:C0679228
Rheumatology	I:C0679228
(	I:C0679228
ACR	I:C0679228
)	I:C0679228
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
.	O

The	O
European	O
criteria	I:C0679228
,	O
American	B:C0679228
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
(	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
)	O
and	O
American	O
College	I:C0679228
of	I:C0679228
Rheumatology	I:C0679228
(	I:C0679228
ACR	I:C0679228
)	I:C0679228
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
.	O

The	O
European	O
criteria	I:C0679228
,	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
(	O
American	B:C0679228
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
)	O
and	O
American	O
College	I:C0679228
of	I:C0679228
Rheumatology	I:C0679228
(	I:C0679228
ACR	I:C0679228
)	I:C0679228
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
.	O

The	O
European	O
criteria	I:C0679228
,	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
(	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
)	O
and	O
American	B:C0679228
College	I:C0679228
of	I:C0679228
Rheumatology	I:C0679228
(	I:C0679228
ACR	I:C0679228
)	I:C0679228
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
.	O

Majority	O
of	O
the	O
patients	O
were	O
women	B:C0043210
(	O
F/	O
M	O
was	O
20/1	O
)	O
.	O

The	O
median	O
duration	O
from	O
the	O
first	O
pSS	B:C0151449
-	I:C0151449
related	I:C0151449
symptom	O
to	O
diagnosis	O
was	O
significantly	O
shorter	O
in	O
men	O
(	O
2.5	O
±	O
2.3	O
vs	O
4.3	O
±	O
5.9	O
years	O
)	O
(	O
p	O
=	O
0	O
<	O
0.016	O
)	O
.	O

The	O
median	O
duration	O
from	O
the	O
first	O
pSS	O
-	I:C0151449
related	I:C0151449
symptom	B:C1457887
to	O
diagnosis	O
was	O
significantly	O
shorter	O
in	O
men	O
(	O
2.5	O
±	O
2.3	O
vs	O
4.3	O
±	O
5.9	O
years	O
)	O
(	O
p	O
=	O
0	O
<	O
0.016	O
)	O
.	O

The	O
median	O
duration	O
from	O
the	O
first	O
pSS	O
-	I:C0151449
related	I:C0151449
symptom	O
to	O
diagnosis	B:C0011900
was	O
significantly	O
shorter	O
in	O
men	O
(	O
2.5	O
±	O
2.3	O
vs	O
4.3	O
±	O
5.9	O
years	O
)	O
(	O
p	O
=	O
0	O
<	O
0.016	O
)	O
.	O

The	O
median	O
duration	O
from	O
the	O
first	O
pSS	O
-	I:C0151449
related	I:C0151449
symptom	O
to	O
diagnosis	O
was	O
significantly	O
shorter	O
in	O
men	B:C0025266
(	O
2.5	O
±	O
2.3	O
vs	O
4.3	O
±	O
5.9	O
years	O
)	O
(	O
p	O
=	O
0	O
<	O
0.016	O
)	O
.	O

When	O
the	O
European	B:C0679228
,	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
and	O
ACR	O
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
,	O
666	O
patients	O
(	O
79.9	O
%	O
)	O
satisfied	O
at	O
least	O
one	O
of	O
them	O
.	O

When	O
the	O
European	O
,	O
American	B:C0679228
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
and	O
ACR	O
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
,	O
666	O
patients	O
(	O
79.9	O
%	O
)	O
satisfied	O
at	O
least	O
one	O
of	O
them	O
.	O

When	O
the	O
European	O
,	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
and	O
ACR	B:C0679228
Sjogren	I:C0679228
's	I:C0679228
criteria	I:C0679228
were	O
applied	O
,	O
666	O
patients	O
(	O
79.9	O
%	O
)	O
satisfied	O
at	O
least	O
one	O
of	O
them	O
.	O

In	O
total	O
,	O
539	O
patients	O
(	O
64.4	O
%	O
)	O
satisfied	O
the	O
European	B:C0679228
,	O
439	O
(	O
52.6	O
%	O
)	O
satisfied	O
the	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
,	O
and	O
359	O
(	O
43	O
%	O
)	O
satisfied	O
the	O
ACR	O
criteria	I:C0679228
.	O

In	O
total	O
,	O
539	O
patients	O
(	O
64.4	O
%	O
)	O
satisfied	O
the	O
European	O
,	O
439	O
(	O
52.6	O
%	O
)	O
satisfied	O
the	O
American	B:C0679228
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
,	O
and	O
359	O
(	O
43	O
%	O
)	O
satisfied	O
the	O
ACR	O
criteria	I:C0679228
.	O

In	O
total	O
,	O
539	O
patients	O
(	O
64.4	O
%	O
)	O
satisfied	O
the	O
European	O
,	O
439	O
(	O
52.6	O
%	O
)	O
satisfied	O
the	O
American	O
-	I:C0679228
European	I:C0679228
Consensus	I:C0679228
Group	I:C0679228
,	O
and	O
359	O
(	O
43	O
%	O
)	O
satisfied	O
the	O
ACR	B:C0679228
criteria	I:C0679228
.	O

Among	O
the	O
entire	O
group	O
,	O
250	O
patients	O
(	O
29.9	O
%	O
)	O
satisfied	O
all	O
and	O
168	O
(	O
20.1	O
%	O
)	O
met	O
none	O
of	O
the	O
criteria	B:C0679228
.	O

The	O
rates	O
of	O
extraglandular	O
organ	B:C0178784
involvements	O
were	O
not	O
different	O
between	O
patients	O
who	O
met	O
at	O
least	O
one	O
of	O
the	O
criteria	O
sets	O
and	O
those	O
who	O
met	O
none	O
.	O

The	O
rates	O
of	O
extraglandular	O
organ	O
involvements	O
were	O
not	O
different	O
between	O
patients	O
who	O
met	O
at	O
least	O
one	O
of	O
the	O
criteria	B:C0679228
sets	O
and	O
those	O
who	O
met	O
none	O
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
the	O
modification	B:C3840684
of	O
the	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
criteria	O
sets	O
to	O
prevent	O
exclusion	O
of	O
patients	O
with	O
extraglandular	O
involvements	O
as	O
the	O
dominant	O
clinical	I:C0243095
features	I:C0243095
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
the	O
modification	O
of	O
the	O
primary	B:C0151449
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
criteria	O
sets	O
to	O
prevent	O
exclusion	O
of	O
patients	O
with	O
extraglandular	O
involvements	O
as	O
the	O
dominant	O
clinical	I:C0243095
features	I:C0243095
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
the	O
modification	O
of	O
the	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
criteria	B:C0679228
sets	O
to	O
prevent	O
exclusion	O
of	O
patients	O
with	O
extraglandular	O
involvements	O
as	O
the	O
dominant	O
clinical	I:C0243095
features	I:C0243095
.	O

There	O
is	O
an	O
urgent	O
need	O
for	O
the	O
modification	O
of	O
the	O
primary	O
Sjogren	I:C0151449
's	I:C0151449
syndrome	I:C0151449
criteria	O
sets	O
to	O
prevent	O
exclusion	O
of	O
patients	O
with	O
extraglandular	O
involvements	O
as	O
the	O
dominant	B:C0243095
clinical	I:C0243095
features	I:C0243095
.	O

